Cell therapy for factor V deficiency: an approach based on human decidua mesenchymal stem cells
dc.contributor.author | Serrano, Luis | |
dc.contributor.author | De la Torre, Paz | |
dc.contributor.author | Liras, Antonio | |
dc.contributor.author | Flores, Ana | |
dc.date.accessioned | 2023-06-16T14:19:34Z | |
dc.date.available | 2023-06-16T14:19:34Z | |
dc.date.issued | 2021 | |
dc.description | CRUE-CSIC (Acuerdos Transformativos 2021) | |
dc.description.abstract | Deficiency of factor V is a congenital autosomal recessive coagulopathy associated with mutations in the F5 gene that results in mild-to-severe bleeding episodes. Factor V is a component of the prothrombinase complex responsible for accelerating conversion of prothrombin to thrombin. At the present time there are no therapeutic factor V concentrates available. This study was designed to lay the preliminary foundations for future cell-based therapy for patients with severe factor V deficiency. The study showed that hepatospheres, which produce coagulation factors VIII, IX, and V, synthetize and store intracellular glycogen and express albumin levels up to 8 times higher than those of undifferentiated cells. Factor IX and factor V gene expression increased significantly in hepatospheres as compared to undifferentiated cells, whereas factor VIII gene expression remained constant. The factor V protein was detected in the hepatospheres´ secretome. Considering the enormous potential of mesenchymal stem cells as therapeutic agents, this study proposes a highly reproducible method to induce differentiation of mesenchymal stem cells from human placenta to factor V-producing hepatospheres. This strategy constitutes a preliminary step towards a curative treatment of factor V deficiency through advanced therapies such as cell therapy. | |
dc.description.department | Depto. de Genética, Fisiología y Microbiología | |
dc.description.faculty | Fac. de Ciencias Biológicas | |
dc.description.refereed | TRUE | |
dc.description.sponsorship | Ministerio de Economía y Competitividad (MINECO)/Instituto de Salud Carlos III | |
dc.description.sponsorship | Comunidad de Madrid/FEDER | |
dc.description.sponsorship | Asociación Andaluza de Hemofilia/Octapharma S.A | |
dc.description.sponsorship | Soria Melguizo Foundation | |
dc.description.status | pub | |
dc.eprint.id | https://eprints.ucm.es/id/eprint/70213 | |
dc.identifier.doi | 10.1016/j.biopha.2021.112059 | |
dc.identifier.issn | 0753-3322 | |
dc.identifier.officialurl | https://doi.org/10.1016/j.biopha.2021.112059 | |
dc.identifier.uri | https://hdl.handle.net/20.500.14352/4688 | |
dc.issue.number | 112059 | |
dc.journal.title | Biomedicine & pharmacotherapy | |
dc.language.iso | eng | |
dc.page.final | 8 | |
dc.page.initial | 1 | |
dc.publisher | Elsevier | |
dc.relation.projectID | (PI15/01803) | |
dc.relation.projectID | (S2013/MIT-2862-CM) | |
dc.relation.projectID | (ASANHEMO FV2016–20) | |
dc.relation.projectID | (PI2013/0116) | |
dc.rights | Atribución-NoComercial-SinDerivadas 3.0 España | |
dc.rights.accessRights | open access | |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/3.0/es/ | |
dc.subject.cdu | 616.151.5 | |
dc.subject.cdu | 615.361.018.1 | |
dc.subject.keyword | Inherited coagulopathies | |
dc.subject.keyword | Severe human factor V | |
dc.subject.keyword | Deficiency | |
dc.subject.keyword | Cell therapy | |
dc.subject.keyword | Human decidua | |
dc.subject.keyword | Mesenchymal stem cells | |
dc.subject.keyword | Hepatocytes | |
dc.subject.ucm | Hematología | |
dc.subject.ucm | Biotecnología | |
dc.subject.unesco | 3205.04 Hematología | |
dc.subject.unesco | 3399 Otras Especialidades Tecnológicas | |
dc.title | Cell therapy for factor V deficiency: an approach based on human decidua mesenchymal stem cells | |
dc.type | journal article | |
dc.volume.number | 142 | |
dspace.entity.type | Publication |
Download
Original bundle
1 - 1 of 1
Loading...
- Name:
- Serrano L. J. 2021. Cell therapy for factor V deficiency.....pdf
- Size:
- 6.09 MB
- Format:
- Adobe Portable Document Format